β-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells

Molecular Cancer Research

Volumn 7, Issue 7, 2009, Pages 1064-1077

  Li, Timothy T ^a   Alemayehu, Mistre ^a   Aziziyeh, Adel I ^a   Pape, Cynthia ^a   Pampillo, Macarena ^a   Postovit, Lynne Marie ^a   Mills, Gordon ^b   Babwah, Andy V ^a   Bhattacharya, Moshmi ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; PROTEIN RALA; PROTEIN RALB; RAL PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ARRESTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; EPITHELIAL CELLS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RAL GTP-BINDING PROTEINS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 67651151233     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0578     Document Type: Article

References (52)

1. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling.Bioessays 2004;26:870-81.
2. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry.Anal Biochem 2001;292:287-95.
3. Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 2000;58:1188-96.
4. T abata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor.Bioc hem Biophys Res Commun 2007;363:861-6.
5. Lee CW, Rivera R, Dubin AE, Chun J. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G (12/13)-mediated Rho activation.J Biol Chem 2007;282:4310-7.
6. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589-97.
7. Pasternack SM, von Kugelgen I, Aboud KA, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth.Nat Genet 2008;40:329-34.
8. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer.Nat Rev Cancer 2003;3:582-91.
9. Stahle M, Veit C, Bachfischer U, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK.J Cell Sci 2003;116:3835-46.
10. Bian D, Su S, Mahanivong C, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway.Ca ncer Res 2004;64: 4209-17.
11. Hao F, Tan M, Xu X, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38á.Bioc him Biophys Acta 2007;1771:883-92.
12. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006;103:9643-8.
13. K itayama J, Shida D, Sako A, et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma.Breast Cancer Res 2004;6: R640-6.
14. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003;13:419-25.
15. W ard Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways.Mol Cell Biol 2001;21:5958-69.
16. Rosario M, Paterson HF, Marshall CJ. Activation of the Ral and phosphatidylinositol 3¡ä kinase signaling pathways by the ras-related protein TC21.Mol Cell Biol 2001;21:3750-62.
17. Y u Y, Feig LA. Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells.Oncogene 2002;21:7557-68.
18. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility.Ca ncer Res 2002;62:982-5.
19. Bhattacharya M, Anborgh PH, Babwah AV, et al. â-Arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization.N at Cell Biol 2002;4:547-55.
20. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by â-arrestins. Science 2005;308:512-7.
21. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling.Pharmacol Rev 2001;53:1-24.
22. Urs NM, Jones KT, Salo PD, Severin JE, Trejo J, Radhakrishna H. A requirement for membrane cholesterol in the â-arrestin- and clathrin-dependent endocytosis of LPA1 lysophosphatidic acid receptors.J Cell Sci 2005;118: 5291-304.
23. Fong AM, Premont RT, Richardson RM, Yu YR, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in â-arrestin2- and GRK6-deficient mice.Proc Natl Acad Sci U S A 2002;99:7478-83.
24. Chen M, Towers LN, O'Connor KL. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.Am J Physiol Cell Physiol 2007;292:C1927-33.
25. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells.Nat Methods 2007;4:359-65.
26. Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.J Biol Chem 2004;279:9653-61.
27. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
28. Ma tsubara K, Kishida S, Matsuura Y, Kitayama H, Noda M, Kikuchi A. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. Oncogene 1999;18:1303-12.
29. DeFea KA. Stop that cell! â-arrestin-dependent chemotaxis: a tale of localized actin assembly and receptor desensitization.Annu Rev Physiol 2007;69: 535-60.
30. Oxford G, Owens CR, Titus BJ, et al. RalA and RalB: antagonistic relatives in cancer cell migration.Cancer Res 2005;65:7111-20.
31. Hofer F, Berdeaux R, Martin GS. Ras-independent activation of Ral by a Ca (2+)-dependent pathway.Curr Biol 1998;8:839-42.
32. Bou charaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
33. Horak CE, Mendoza A, Vega-Valle E, et al. Nm23-1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.Cancer Res 2007;67:11751-9.
34. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.Cancer Res 2001;61:3194-9.
35. Shida D, Kitayama J, Yamaguchi H, et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells.Exp Cell Res 2004;301: 168-78.
36. Y amada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.J Biol Chem 2004;279:6595-605.
37. Bian D, Mahanivong C, Yu J, et al. The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration.Oncogene 2006;25:2234-44.
38. Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.Biochim Biophys Acta 2008.
39. Beckman KB, Lee KY, Golden T, Melov S. Gene expression profiling in mitochondrial disease: assessment of microarray accuracy by high-throughput Q-PCR.Mitochondrion 2004;4:453-70.
40. Contos JJ, Ishii I, Fukushima N, et al. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2).Mol Cell Biol 2002;22:6921-9.
41. W ang D. Discrepancy between mRNA and protein abundance: insight from information retrieval process in computers.Comput Biol Chem 2008.
42. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA. â-Arrestindependent regulation of the cofilin pathway downstream of protease-activated receptor-2.J Biol Chem 2007;282:20634-46.
43. Wang P, Gao H, Ni Y, et al. â-Arrestin 2 functions as a G-proteincoupled receptor-activated regulator of oncoprotein Mdm2.J Biol Chem 2003; 278:6363-70.
44. Chen W, Kirkbride KC, How T, et al. â-Arrestin 2 mediates endocytosis of type III TGF-â receptor and down-regulation of its signaling.Science 2003;301: 1394-7.
45. Zou L, Yang R, Chai J, Pei G. Rapid xenograft tumor progression in â-arrestin1 transgenic mice due to enhanced tumor angiogenesis.F ASEB J 2008;22:355-64.
46. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. Depletion of â-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer.J Immunol 2008;180:5699-706.
47. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.Cancer Cell 2005;8:393-406.
48. Smith SC, Oxford G, Baras AS, et al. Expression of ral GTPases, their effectors, and activators in human bladder cancer.Clin Cancer Res 2007;13: 3803-13.
49. Yin J, Pollock C, Tracy K, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.Mol Cell Biol 2007;27:7538-50.
50. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform.Nat Rev Cancer 2008;8:133-40.
51. Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP. The small GTPase RalA targets filamin to induce filopodia.Pro c Natl Acad Sci U S A 1999;96: 2122-8.
52. Scott MG, Pierotti V, Storez H, et al. Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and â-arrestins.Mol Cell Biol 2006;26:3432-45.